Understanding how new antibiotics can overcome resistance in harmful bacteria
Official title: Susceptibility and resistance of multidrug-resistant gram-negative bacteria to novel beta-lactam/beta-lactamase inhibitor combinations
Funded at Beth Israel Deaconess Medical Center · NIH-10899601 · Data updated 2026-11-12
This study is looking at new combinations of antibiotics to help fight tough infections caused by bacteria like E. coli and Pseudomonas aeruginosa, so that patients can have better treatment options and reduce the chances of the bacteria becoming resistant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 7, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $466,211 |
| NIH project number | 5R01AI178875-02 |
| Project ID | NIH-10899601 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by multidrug-resistant gram-negative bacteria.
✕Less likely to help
Patients with infections caused by bacteria that are not multidrug-resistant may not benefit from this research.
What this research studies
This research investigates new combinations of antibiotics that include novel compounds designed to combat multidrug-resistant gram-negative bacteria like E. coli and Pseudomonas aeruginosa. The approach focuses on understanding how these new antibiotics work and how bacteria might develop resistance against them. By studying various strains of bacteria, the research aims to identify effective treatment strategies while minimizing the risk of resistance development. Patients may benefit from improved treatment options for infections caused by resistant bacteria.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibiotics for treating serious infections caused by resistant bacteria.
How similar studies have gone: Other research has shown promise in developing new antibiotic combinations to combat bacterial resistance, indicating that this approach has potential for success.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Brennan-Krohn, Thea — Beth Israel Deaconess Medical Center
- Study coordinator: Brennan-Krohn, Thea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.